•  

Posts Tagged: surgery

Funding call: MaRS Innovation Industry Access Program (MI-IAP) accepting applications to February 6

Researchers working in orphan indications, immuno-oncology, respiratory diseases, diabetes, and other key areas invited to submit a brief Statement of Interest The MaRS Innovation Industry Access Program (MI-IAP) is a simple, formalized process for marketing early-stage technologies to MI's industry partners: Baxter, LifeLabs (formerly CML Healthcare), GSK, Johnson & Johnson, Pfizer and IRICoR/Merck. The program's goal is to secure funding for researchers within MI's membership through these collaborative, strategic R&D partnership programs. The program is open to any researcher affiliated with MI's 16 member ... Read more

OCE invests $250,000 in ScarX Therapeutics’ revolutionary anti-scarring medication

TORONTO, ON (Jan. 24, 2013) - ScarX Therapeutics, a start-up company commercializing a groundbreaking treatment to dramatically reduce post-operation scarring, is receiving a $250,000 investment from Ontario Centres of Excellence. This story was covered in Yonge Street Media on January 30, 2013. ScarX, a topical medication, emerged from Dr. Benjamin Alman's research. Alman, head of orthopedic surgery at the Hospital for Sick Children, is developing his invention in conjunction with MaRS Innovation. Each year, doctors worldwide perform 240 million surgeries. Currently, no clinically-proven prescription ... Read more

ScarX Therapeutics Featured on Front Page of the Globe and Mail

MaRS Innovation's ScarX Therapeutics, a strategic partnership with The Hospital for Sick Children (SickKids) and NovoTek Therapeutics Inc. (NovoTek), was featured on the front page of the Globe and Mail on May 7, 2010. Read the article on Globe and Mail.com (note that depending on when you're accessing this page, the Globe's content may be subject to a pay wall). (more…) Read more

MaRS Innovation Forms Strategic Drug-Development Partnership with NovoTek Therapeutics Inc. in China

MaRS Innovation (MI), The Hospital for Sick Children (SickKids) and NovoTek Therapeutics Inc. (NovoTek)  have announced a strategic partnership to co‐develop, and bring to the Chinese market, a novel therapeutic cream aimed at reducing scar formation post surgery. This project was covered in The Globe and Mail on May 7, 2012. (more…) Read more